On September 9, 2024, Cingulate Inc., a biopharmaceutical company, reinstated the annual base salaries of its top executives to pre-reduction levels, following cost containment measures taken in late 2023. The CEO, COO, and CFO saw their salaries return to $503,000, $424,000, and $350,000 respectively. Additionally, on September 12, 2024, Cingulate announced the commencement of its final FDA-required study for CTx-301, a treatment for ADHD. The company expects a data readout from the study by the end of 2024. Cingulate has also successfully raised over $10 million in additional capital since mid-August 2024, with 58% coming from its at-the-market facility, and has been notified by Nasdaq of its compliance with listing requirements. The company continues to operate with a reduced headcount, maintaining approximately 40% fewer employees compared to 2023, resulting in cumulative cash savings of about $1.45 million.

On September 9, 2024, Cingulate Inc., a biopharmaceutical company, reinstated the annual base salaries of its top executives to pre-reduction levels, following cost containment measures taken in late 2023. The CEO, COO, and CFO saw their salaries return to $503,000, $424,000, and $350,000 respectively. Additionally, on September 12, 2024, Cingulate announced the commencement of its final FDA-required study for CTx-301, a treatment for ADHD. The company expects a data readout from the study by the end of 2024. Cingulate has also successfully raised over $10 million in additional capital since mid-August 2024, with 58% coming from its at-the-market facility, and has been notified by Nasdaq of its compliance with listing requirements. The company continues to operate with a reduced headcount, maintaining approximately 40% fewer employees compared to 2023, resulting in cumulative cash savings of about $1.45 million.